SCHEMBL3462013

SCHEMBL3462013

CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR27 Q9NS67 1/20 0.60
KDM4E B2RXH2 2/20 0.56
MAPT P10636 5/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
LMNA P02545 3/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
TSHR P16473 2/20 0.54
TP53 P04637 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
NOX1 Q9Y5S8 1/20 0.54
KCNJ6 P48051 2/20 0.51
KCNJ5 P48544 2/20 0.51
KCNJ3 P48549 2/20 0.51
ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7805821 0.89 KCNJ6 (0.53) GPR27KDM4EMAPTMEN1KMT2A
SCHEMBL3462570 0.85 KCNJ6 (0.51) GPR27MAPTMEN1KMT2ALMNA
SCHEMBL3461743 0.81 MCOLN3 (0.71) GPR27KDM4EMAPTMEN1KMT2A
SCHEMBL7803996 0.81 TSHR (0.58) GPR27KDM4EMAPTMEN1KMT2A
SCHEMBL4879959 0.79 KDM4E (0.59) GPR27KDM4EMAPTMEN1KMT2A
SCHEMBL7807959 0.78 KDM4E (0.51) GPR27KDM4EMAPTMEN1KMT2A
SCHEMBL15824721 0.78 SIRT2 (0.67) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL7806612 0.77 KCNJ6 (0.56) MAPTMEN1KMT2ALMNANPC1
SCHEMBL4175247 0.77 KDM4E (0.51) GPR27KDM4EMAPTMEN1KMT2A
SCHEMBL13631963 0.77 GPR27 (0.44) GPR27KDM4EMAPTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 WO disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES ITGA1, ITGB1, ITGA2B GPR27 1464/4885KDM4E 671/4885MAPT 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.